Skip to content

Building Team Science – Opportunities to Propose Ancillary Studies to the Framingham Heart Study

November 1, 2013

three heart logoAs described in the previous post, “Transformation is in the air…future directions in epidemiology,” the NHLBI described a planned limited contract renewal of the Framingham Heart Study. The new contract, to start in 2015, will begin the transformation of epidemiology and will have a different structure and format from the previous scientific work scope. Consequently, Framingham Heart Study investigators are encouraging collaboration with interested outside investigators to assemble a portfolio of investigator-initiated grant applications for innovative research that involves new data collection from the participants. If you are interested, now is the time to contact the Framingham Heart Study.

Interested investigators should consider the following as they begin this process:

• The study has its own policies, procedures, and timeline for reviewing and approving ancillary study proposals before a grant application may be submitted for funding.
• Consultation with the study is necessary to ensure the proposed research is appropriate for the study population, ascertain existing data availability, and determine resource needs.

Submission of applications proposing new data collection in study participants should be coordinated so the participant exam components can be conducted in a single participant visit, in order to minimize participant burden and cost.

If you are interested, please visit the study web site via the links provided above, or contact the study directly. The study has announcements regarding this collaborative application process and can provide the necessary information to proceed.

Prepared by the Epidemiology Branch

2 Comments leave one →
  1. Patrick O'Connor, MD, MPH permalink
    November 7, 2013 9:43 am

    1.) I assume there is no FRS for those age 20-35, or for adolescents. Is that correct? If so, an important goal would be to develop a FRS for lifetime CVD risk for those age 20-35 years old.

    2.) Another useful tool would be an equation that simultaneously includes Aspirin use (0/1), BMI, LIPIDS, as well as the other stuff. This is not based on epidemiologic efforts to generate parsimonious models, but at real-life clinical decision support applications, which need to consider multiple pathways (independent effects or not) that may be available for patients to follow to reduce their CV risk.

    3.) Another improvement would be to include A1c or fasting glucose values instead of a 0/1 for diabetes.

    4.) Closer examination of legacy effects or “area under the curve” for BP, lipids, or A1c over the last 3-5 years would be a possible area for exploration.

    5.) Managing to correctly assess use of statins is tough, ,but worth trying to do. One way might be to compute an “untreated LDL” based on the actual L DL corre4cted for the dose of statin a person is taking.

  2. December 3, 2013 11:46 am

    Lot’s of exciting developments in many areas can be tested and validated in the Framingham (and other well-studied) cohorts. Just noticed this commentary (and related articles) on use of electronic health records to study phenotypes: http://jamia.bmj.com/content/20/e2/e226?etoc Many technologies developed outside of Framingham can be validated in the Framingham databases.

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 131 other followers

%d bloggers like this: